ライフサイエンスコーパス: RVF

1 RVF developed in 193 of 798 patients (24.2%) in the deri

2 RVF epidemics mostly occur in Africa and can decimate li

3 RVF is caused by Rift Valley fever virus (RVFV; family B

4 RVF is exotic to the United States; however, mosquito sp

5 RVF is of global concern, having expanded its geographic

6 RVF transmission is associated with the occurrence of El

7 RVF was associated with significantly reduced RV ejectio

8 and efficacy of the Rift Valley fever MP-12 (RVF MP-12) vaccine, 9 healthy adult Rhesus macaques, wei

9 composing the low-risk group (estimated <20% RVF risk) compared with those in the higher-risk groups.

10 ed the model using data from the recent 2010 RVF outbreak in South Africa as a case study; mapping th

11 ent sequence was obtained from a total of 31 RVF virus specimens spanning the entire known outbreak p

12 his is the first prospective prediction of a RVF outbreak.

13 tem for the reverse genetics generation of a RVF virus replicon particle (VRP(RVF)) vaccine candidate

14 keys (AGM) proved susceptible to aerosolized RVF virus.

15 the absence of liver Lrp1 expression affects RVF pathogenesis.

16 s with those from the 1997-1998 east African RVF outbreak.

17 The causative agent, RVF virus (RVFV), can be naturally transmitted by mosqui

18 An RVF risk calculator (STOP-RVF) was then developed and su

19 .8 mL/s, range 2.5-5.7 mL/s; P < 0.001), and RVF (45%, range 32.5-51.5%; P = 0.006), and clinical imp

20 and regressed pulmonary vascular disease and RVF.

21 1, OF4), calf muscle pump function (EF), and RVF of the stented limbs did not differ significantly fr

22 xistence of both RVF-free (disease-free) and RVF-present (endemic) equilibrium points are established

23 ssessment tool for the prediction of RVF and RVF-associated all-cause mortality.

24 o RVFV in humans and livestock using an anti-RVF immunoglobulin enzyme-linked immunosorbent assay.

25 864 livestock samples were screened for anti-RVF Immunoglobulin G (IgG).

26 ose immunization regimen induced robust anti-RVF virus immunoglobulin G antibodies (titer, approximat

27 The anti-RVF virus (RVFV) IgG seropositivity in livestock and hum

28 In addition, the large Saudi Arabian RVF outbreak in 2000 appears to have involved virus intr

29 We assessed RVF as RV fractional area change by echocardiography at

30 line (MCT, 60 mg/kg) to induce PH-associated RVF (PH, n=24) or saline (control, n=17).

31 The mutagen-attenuated RVF MP-12 vaccine was determined to be protective agains

32 Baseline RVF did not modify the treatment effect of CRT on the pr

33 ve implications for further studies of basic RVF virus ecology and the design of future surveillance/

34 Patients with the best RVF at 1 year demonstrated the lowest subsequent event r

35 The existence of both RVF-free (disease-free) and RVF-present (endemic) equili

36 cember-May) and geographic areas affected by RVF virus activity.

37 -12 vaccine is one of the best-characterized RVF vaccines for safety and efficacy and is currently co

38 The primary outcome was the composite RVF rate after both operations, defined after transplant

39 al transmission in a rat model of congenital RVF.

40 vaccination appear to be key to controlling RVF in this setting.

41 romboembolic pulmonary hypertension (CTEPH) (RVF, n = 10; no RVF, n = 16).

42 Bayesian analysis of current RVF virus genetic diversity places the most recent commo

43 mathematical metapopulation model describing RVF virus transmission in livestock across the four isla

44 For patients who developed RVF after LVAD implantation, there was a 45% increase in

45 ration continuous mechanical assist devices, RVF after implantation of LVAD is still associated with

46 genome sequence was achieved for 33 diverse RVF virus strains collected from throughout Africa and S

47 Existing RVF prediction models exhibit heterogeneous derivation a

48 a (ER-a), attenuates PAH-induced RV failure (RVF) by upregulating the procontractile and prosurvival

49 icle (LV) in right ventricular (RV) failure (RVF) after RV pressure overload.

50 models predicting right ventricular failure (RVF) after durable left ventricular assist device (LVAD)

51 eloped to predict right ventricular failure (RVF) after left ventricular assist device (LVAD) placeme

52 ecent insights on right-ventricular failure (RVF) following left-ventricular assist device (LVAD) imp

53 hypertension and right ventricular failure (RVF) in left ventricular systolic dysfunction (LVSD) is

54 Right ventricular failure (RVF) in pulmonary hypertension (PH) is associated with i

55 Right ventricular failure (RVF) is a cause of major morbidity and mortality after l

56 Right ventricular failure (RVF) is a leading driver of morbidity and death after ma

57 lts in death from right ventricular failure (RVF).

58 Rift Valley fever (RVF) and brucellosis are serious zoonotic diseases with

59 disease manifestations of Rift Valley fever (RVF) in humans include hemorrhagic fever, ocular disease

60 The emergence of Rift Valley fever (RVF) in the Middle East, and its continuing presence in

61 Rift Valley fever (RVF) is a mosquito-borne viral disease endemic to Africa

62 Rift Valley fever (RVF) is a mosquito-borne viral zoonosis showing complex

63 Rift Valley fever (RVF) is a mosquito-borne zoonotic disease endemic to Afr

64 Rift Valley fever (RVF) is a mosquito-transmitted viral disease that is end

65 Rift Valley fever (RVF) is a vector-borne viral disease widespread in Afric

66 Rift Valley fever (RVF) is a veterinary and human disease in Africa and the

67 Rift Valley Fever (RVF) is a zoonosis transmitted by Aedes and Culex mosqui

68 Rift Valley fever (RVF) is a zoonotic and vector-borne disease, mainly pres

69 Rift Valley fever (RVF) is a zoonotic disease endemic in Africa and the Ara

70 Rift Valley fever (RVF) is an emerging, zoonotic, arboviral hemorrhagic fev

71 Although Rift valley fever (RVF) is endemic in Mauritania, with 8 epidemics document

72 Rift Valley fever (RVF) is endemic to Africa, and the mosquito-borne diseas

73 Rift Valley fever (RVF) is one of the neglected tropical diseases in Africa

74 ue-forming units (pfu) of Rift Valley fever (RVF) MP-12 vaccine by oral, intranasal drops, or small p

75 A Rift Valley fever (RVF) risk mapping model using these climate data predict

76 Rift Valley fever (RVF) virus (RVFV) can cause severe human disease charact

77 generation of infectious Rift Valley fever (RVF) virus from cloned cDNA using Vero cells, which are

78 Rift Valley fever (RVF) virus historically has caused widespread and extens

79 Rift Valley fever (RVF) virus is a mosquito-borne human and veterinary path

80 Rift Valley fever (RVF) virus is a mosquito-borne RNA virus responsible for

81 Rift Valley fever (RVF) virus is a mosquito-borne virus associated with lar

82 As Rift Valley fever (RVF) virus, and probably all members of the family Bunya

83 fter the first reports of Rift Valley fever (RVF) were documented in Kenya, questions on the transmis

84 persistence mechanisms of Rift Valley fever (RVF), a zoonotic arboviral haemorrhagic fever, at both l

85 Rift Valley fever (RVF), an emerging mosquito-borne zoonotic infectious vir

86 Rift Valley fever (RVF), which has been designated as a priority disease by

87 results of surgery for rectovaginal fistula (RVF) and prognostic factors for success.

88 for the first time to a rapid vertical flow (RVF) immunotechnology for detection of anti-HCV antibodi

89 ntly there are no therapeutics available for RVF patients.

90 these, 184 samples were tested via ELISA for RVF virus antibodies (IgG and IgM), while all 200 were s

91 Therefore, Lrp1 is essential for RVF hepatic disease in mice.

92 d vectors could be the primary mechanism for RVF viral persistence in endemic areas.

93 he existing nonhuman primate (NHP) model for RVF utilizes an intravenous (i.v.) exposure route in rhe

94 tudy presents a novel mathematical model for RVF, taking into account time-dependent treatment, vacci

95 he performance of risk prediction models for RVF in adult patients undergoing LVAD implantation.

96 All patients operated for RVF from 1996 to 2014 were included.

97 g iEPO was associated with similar risks for RVF development and development of other postoperative s

98 p between simulated climatic suitability for RVF transmission and large-scale climate modes of variab

99 A live-attenuated vaccine for RVF, the MP-12 vaccine, is conditionally licensed for ve

100 urrently, there are no licensed vaccines for RVF that are both safe and efficacious.

101 afe and efficacious recombinant vaccines for RVF.

102 risk models have been developed to forecast RVF transmission risk but very few studies have validate

103 and hypertension [Residual Venous Fraction (RVF) in %], were examined before and after successful ve

104 lling index [VFI], residual volume fraction [RVF]) and venous duplex, treadmill (3.5 km/h, 10%) to de

105 Right ventricular function (RVF) is an important determinant of outcome in patients

106 ge points was prespecified for between-group RVF risk difference.

107 model to seroprevalence livestock and human RVF case data from the 2018-2019 epidemic in Mayotte to

108 et model more closely resembles severe human RVF disease and is therefore an ideal model for the eval

109 inant RVFV vaccines for human use.IMPORTANCE RVF is a mosquito-transmitted, viral, zoonotic disease e

110 and anthropogenic factors are implicated in RVF spread, the multidisciplinary One Health approach wa

111 was associated with a greater improvement in RVF (DeltaRV fractional area change 8.1% versus 5.4%; P<

112 1% versus 5.4%; P<0.001), and improvement in RVF was related to subsequent outcomes.

113 toms, CRT was associated with improvement in RVF, which improved in parallel with improvement in left

114 Instead, impulse transmission in RVF was hampered by reduction in cell length (111.6 +/-

115 F), worse CEAP clinical class, and increased RVF (all, P < 0.05).

116 The LV of rats with MCT-induced RVF exhibited electrophysiologic remodeling: longer acti

117 PH-induced RVF is associated with a distinct phase of increased mor

118 dies of the LV in rats with pressure-induced RVF (monocrotaline [MCT] injection, n = 25; controls wit

119 The LV in pressure-induced RVF develops dysfunction, reduction in mass, and altered

120 Pressure-induced RVF is associated with electrophysiologic remodeling of

121 Following initial RVF virus laboratory confirmation, a high-throughput RVF

122 mechanical circulatory support for isolated RVF, and defined after left ventricular assist device im

123 ic assays is illustrated by testing of known RVF case materials obtained during the Saudi Arabia outb

124 LRVF was able to correctly reproduce major RVF epidemics in Somalia, Kenya, Zambia and to a lesser

125 South Africa has experienced three major RVF epidemics (1950-51, 1973-75 and 2008-11).

126 These rationally designed marker RVF vaccine viruses will be useful tools for in vitro sc

127 hanical Circulatory Support Research Network RVF models.

128 monary hypertension (CTEPH) (RVF, n = 10; no RVF, n = 16).

129 revention and early detection in the case of RVF resurgence in the region.

130 The definition of RVF as an outcome was heterogenous among models.

131 dation methodologies, varying definitions of RVF, and are mostly derived from single centers.

132 l provide a basis for further development of RVF virus marker vaccines for use in endemic regions or

133 proach was needed to identify the drivers of RVF epidemics in Madagascar.

134 nvironmental factors are the main drivers of RVF infection in humans can be used to design better pre

135 o insights into the evolution and ecology of RVF virus, these genomic data also provide a foundation

136 Evidence of RVF infection was found in 9.2% of animals tested and ac

137 vides the first overview of the evolution of RVF epidemiology in Nouakchott and the serological evide

138 d reconstruct the epidemiological history of RVF virus (RVFV) circulation within the city.

139 Management of RVF remains challenging and numerous surgical options ar

140 We propose a new compartmentalized model of RVF and the related ordinary differential equations to a

141 that cattle had a 2.9-fold elevated odds of RVF IgG seropositivity relative to sheep and goats (OR =

142 mate data predicted areas where outbreaks of RVF in humans and animals were expected and occurred in

143 to help mitigate the devastating outcomes of RVF ocular disease through vaccines or treatments.

144 ans to better understand the pathogenesis of RVF and to use for evaluation of medical countermeasures

145 current understanding of the pathogenesis of RVF encephalitis.

146 d risk assessment tool for the prediction of RVF and RVF-associated all-cause mortality.

147 Wedge Pressure ratio) were not predictive of RVF in our cohort.

148 , risk factors, and ecological predictors of RVF in humans and livestock during an interepidemic peri

149 with one study estimating the prevalence of RVF to be 2.3% in females with Crohn's disease.

150 Few large reports of RVF are available and success prognostic factors remain

151 DMI are associated with an increased risk of RVF over the Horn of Africa, with important time lags.

152 dies have tried to better define the risk of RVF using combined clinical scores and measures of right

153 t study were to assess the seroprevalence of RVF in humans and reconstruct the epidemiological histor

154 The Golgi localization signal of RVF virus has been shown to reside within the G(N) prote

155 of detecting the natural genetic spectrum of RVF viruses.

156 Further spread of RVF into countries where the disease is not endemic may

157 ion could improve the risk stratification of RVF following LVAD implantation.

158 gested that aggressive surgical treatment of RVF, including early use of temporary stoma and major pr

159 ce and continuous public health education on RVF infection and prevention during interepidemic period

160 This review highlights recent research on RVF, focusing on vectors and their ecology, transmission

161 outbreak also was found, indicating ongoing RVF virus activity and evolution during the interepizoot

162 ent of patients (100/254) had post-operative RVF, of which 9% (23/254) required prolonged inotropic s

163 Meanwhile, as of 2015, no other RVF vaccine has been conditionally or fully licensed for

164 The concept that PAH RVF results from RV inflammation rather than solely from

165 NLRP3 inflammasome in RV macrophages to PAH RVF.

166 activity was evaluated in patients with PAH RVF.

167 We report here the establishment of a pan-RVF virus quantitative real-time reverse transcription-P

168 tion and medical management of postoperative RVF.

169 lant variables associated with postoperative RVF included nonischemic cardiomyopathy, intra-aortic ba

170 necessary to enhance our ability to predict RVF after LVAD implantation.

171 Seventy-nine patients presented RVF due to Crohn disease in 34 (43%), postoperative in 2

172 taining-3)-macrophage activation may promote RVF in PAH.

173 uracy was compared with previously published RVF scores.

174 ease and treatment burden of Crohn's-related RVF and AVF and identifies multiple evidence gaps in thi

175 (SLR) assessed the burden of Crohn's-related RVF and AVF, summarizing evidence from observational stu

176 rience and disease burden of Crohn's-related RVF and AVF.

177 ift Valley Fever model (LRVF) in reproducing RVF epidemics over Africa and to explore the relationshi

178 lop a nonhuman primate (NHP) model of severe RVF in humans to better understand the pathogenesis of R

179 show that the LRVF model correctly simulates RVF transmission hotspots and reproduces large epidemics

180 An RVF risk calculator (STOP-RVF) was then developed and subsequently externally vali

181 cohort study derived and validated the STOP-RVF calculator as a personalized risk assessment tool fo

182 The STOP-RVF risk calculator exhibited a significantly better per

183 nt enhanced green fluorescent protein-tagged RVF viruses containing either the full-length, complete

184 n (EF) had both improved (P < 0.001) and the RVF had decreased (P < 0.001), at the expense of venous

185 notic infectious viral disease caused by the RVF virus (RVFV) (Bunyaviridae: Phlebovirus), presents s

186 ory effect was found only for targets in the RVF (LH), whereas for toddlers learning the color terms,

187 roposed approach for accurately modeling the RVF spreading process in additional regions of the world

188 vide insights into long term behavior of the RVF dynamics in the population, suggesting efficient pre

189 A single inoculation of the RVF MP-12 live attenuated vaccine by the aerosol or intr

190 G(N) chimeric proteins demonstrated that the RVF virus Golgi localization signal mapped to a 48-amino

191 s laboratory confirmation, a high-throughput RVF diagnostic facility was established at the Kenyan Ce

192 , and factors associated with, antibodies to RVF virus (RVFV) in livestock in an area heavily affecte

193 and vector movements among regions is new to RVF modeling.

194 eloped severe PH by day 21 and progressed to RVF by approximately day 30.

195 , and camels are particularly susceptible to RVF and serve as amplifying hosts for the virus.

196 ulmonary hypertension or PVR or uncontrolled RVF after aggressive management with all standard curren

197 e disease, and the only available veterinary RVF vaccine in the United States is a live-attenuated MP

198 en challenged with 1 x 10(5) pfu of virulent RVF virus delivered by a small particle aerosol at 56 da

199 ntly challenged with a high dose of virulent RVF virus survived infection and could be serologically

200 VRP(RVF) can actively synthesize viral RNA and proteins but

201 VRP(RVF) proved to be completely safe following intracranial

202 ration of a RVF virus replicon particle (VRP(RVF)) vaccine candidate.

203 We show that a single subcutaneous VRP(RVF) immunization initiated a systemic antiviral state f

204 Using a mouse model, we show that VRP(RVF) immunization provides the optimal balance of safety

205 ngle-dose subcutaneous immunization with VRP(RVF), although it is highly attenuated, completely prote

206 The primary outcome was RVF incidence, defined as the need for RV assist device

207 has quantified risk factors associated with RVF epidemics in animals in South Africa.

208 mporal environmental factors associated with RVF incidence.

209 ns, elevation was negatively associated with RVF virus exposure.

210 of human and animal illness consistent with RVF virus infection emerged across semiarid regions of t

211 The LV of patients with CTEPH with RVF also exhibited ERP prolongation (306 +/- 8 ms vs. 26

212 picardial mapping of the LV in patients with RVF after chronic thromboembolic pulmonary hypertension

213 creased in RV homogenates from patients with RVF and from rats with maladaptive (but not adaptive) RV

214 dies indicate that the coupling of SERS with RVF technology shows enormous potential for next-generat

215 IMPORTANCE The zoonosis RVF virus (RVFV) is one of the most serious arbovirus th